Developing innovative drug delivery technologies to eliminate the burden of multiple daily fertility treatment injections for women.
Maman Biomedical is developing the world’s first needle-free hormonal patch for fertility treatment, replacing 20+ daily subcutaneous injections with a painless, user-friendly microneedle device. Built on 13+ years of materials science, encapsulation, and sustained-release expertise, our platform overcomes traditional transdermal delivery limits and enables controlled, tunable release of large-molecule hormones.
In under two years, we’ve progressed from concept to protected IP, a working prototype, early clinical partnerships, and top-5 placement in many of Canada’s most prestigious startup competitions. We’ve leveraged $500k+ in non-dilutive funding, established lab space for preclinical development, and built a clear regulatory and commercialization roadmap.
While we’re starting with fertility, our platform has broader applications across hormone therapy and specialty drug delivery. We are highly coachable, impact-driven founders with lived experience in the problem we’re solving – and we move fast. With the right partners, we are positioned to become the category leader in needle-free reproductive care and beyond.
SDG 10: Reduced Inequalities; SDG 3: Good Health and Well-Being; SDG 5: Gender Equality; SDG 12: Responsible Consumption and Production; SDG 9: Industry, Innovation, and Infrastructure